Asparagine concentration in plasma after 2500 IU/m2 PEG-asparaginase i.v. in children with acute lymphoblastic leukemia

Klinische Padiatrie

Volumn 217, Issue 6, 2005, Pages 321-326

  Wenner, K A ^a   Vieira Pinheiro, J P ^a   Escherich, C ^a   Wessalowski, R ^b   Jorch, N ^c   Wolff, J ^d   Stehn, M ^a   Kohlschutter A ^a   Boos, J ^a   Janka Schaub, C E ^a,e  

^a UNIVERSITY OF HAMBURG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Gilead Hospital   (Germany)

^d St Hedwig's Hospital   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Acute lymphoblastic leukemia; Asparaginase; Aspraragine; PEG

Indexed keywords

ASPARAGINASE MACROGOL; ASPARAGINE; PHTHALALDEHYDE;

ANTIBODY PRODUCTION; ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HIGH RISK PATIENT; HUMAN; ION EXCHANGE CHROMATOGRAPHY; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; SAMPLE; TIME SERIES ANALYSIS;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; ASPARAGINE; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, ION EXCHANGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; FEMALE; HALF-LIFE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MULTICENTER STUDIES; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 28544434763     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-872516     Document Type: Article

References (25)

1. Appel IM, Pinheiro JP, Den Boer ML, Lanvers C, Reniers NC, Boos J, Pieters R. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia 2003; 17: 2254-2256
2. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comperative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11: 1780-1786
3. Asselin BL, Gelber R, Sallan S. Relative toxicity of E.coli L-asparaginase (ASP) and PEGasparaginase (PEG) in newly diagnosed childhood acute lymphoblastic leukemia (ALL). Med Pediatr Oncol 1993; 21: 556
4. Attarbaschi A, Mann G, Kronberger M, Witt V, Gadner H, Dworzak M. Effects of dose-reduced medac®L-asparaginase on coagulation in trial ALL-BFM2000. Klin Pädiatr 2003; 215: 321-326
5. Becker EE, Broome JD. L-asparagine: inhibition of endogenous RNA polymerase activity in regenerating liver. Arch Biochem Biophys 1969; 130: 332-336
6. Billett AL, Carls A, Gelber RD, Sallan SE. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer 1992; 70: 201-206
7. Boos J, Nowak-Göttl U, Jürgens H, Fleischhack G, Bode U. Loss of activity of Erwinia asparaginase on repeat applications. J Clin Oncol 1995; 13: 2474-2475
8. Broome JD. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. J Exp Med 1963; 118: 121-147
9. Broome JD. L-asparaginase: discovery and development as a tumor-inhibitory agent. Cancer Treat Rep 1981; 65: 111-114
10. Dorr RT, Hoff DD von. Drug monographs - asparaginase. In: Dorr RT, Hoff DD von (eds). Cancer chemotherapy handbook. Appleton and Lange, Norwalk, CT 1994; 201-209
11. Fabry U, Körholz D, Jürgens H, Göbel U, Wahn V. Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children - evidence of a complement-mediated mechanism. Pediatr Res 1985; 19: 400-408
12. Fumarola C, Zerbini A, Guidotti GG. Glutamine deprivation-mediated cell shrinkage induces ligand-independent CD95 receptor signaling and apoptosis. Cell Death Differ 2001; 8: 1004-1013
13. Haley EE, Fischer GA, Welch AD. The requirement for L-Asparagine of mouse leukaemia cells L5178Y in culture. Cancer Res 1961; 21: 532-536
14. Harms D, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukaemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000; 14: 2234-2239
15. Ho D, Thetford B, Carter C, Frei E. Clinical pharmacologic studies of L-asparaginase. Clin Pharmacol Therapeut 1970; 11: 408-417
16. Jürgens H, Schwamborn D, Körholz D, Wahn V, Göbel U. Clinical experience with polyethylene-glycol-1-asparaginase in patients with recurrent all. Klin Pädiatr 1988; 200: 184-189
17. Körholz D, Urbanek R, Nürnberger W, Jobke A, Göbel U, Wahn V. Development of specific IgG-Antibodies during 1-Asparaginase treatment - distribution of IgG-subclasses. Monatsschr Kinderheilkd 1987; 135: 325-328
18. Körholz D, Wahn U, Jürgens H, Wahn V. Allergic reaction during treatment with L-asparaginase - role of specific IgE antibodies. Monatsschr Kinderheilkd 1990; 138: 23-25
19. Kurtzberg J, Asselin BL, Poplack D. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Heamatol Oncol 1993; 34: 304
20. Kurtzberg J. A new look at PEG-L-asparaginase and other asparaginases in haematological malignancies. Cancer Invest 1994; 12 (Suppl 1): 59-60
21. Müller HJ, Boos J. Use of L-asparagine in childhood ALL. Crit Rev Oncol Haematol 1998; 28: 97-113
22. Müller HJ, Löning L, Horn A, Schwabe D, Gunkel M, Schrappe M, Schütz V von, Henze G, da Palma JC, Ritter J, Vieira Pinheiro JP, Winkelhorst M, Boos J. Pegylated asparaginase (Oncaspar®) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol 2000; 110: 379-483
23. 2 BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols. Cancer Chemother Pharmacol 2002; 49: 149-154
24. Stams WA, den Boer M, Beverloo HB, Meijerink Jules PP, Stigter RL, Wering ER van, Janka-Schaub GE, Slater R, Pieters R. Sensitivity to L-Asparaginase is not associated with expression levels of asparagine synthetase in t(12;21) positive pediatric ALL Blood 2003; 101: 2743-2747
25. Vieira Pinheiro JP, Müller HJ, Schwabe D, Gunkel M, da Palma JC, Henze G, Schütz V von, Winkelhorst M, Würthwein G, Boos J. Drug monitoring of low dose PEG-asparaginase (Oncaspar®) in children with relapsed acute lymphoblastic leukaemia. Br J Haematol 2001; 113: 115-119